Genmab — Juni 2018
-
Niels Van de Donk | EHA 2018 | Immunotherapy in myeloma: why, when and how? https://www.youtube.com/watch?v=XKwAGKMBslo
-
this Ixazomib
(ninlaro)/ Dara combi is recruiting again (was suspended) https://clinicaltrials.gov/ct2/history/NCT03012880?A=7&B=8&C=merged -
the MMY2002 (SIRIUS)
study updated its results in clinicaltrials https://clinicaltrials.gov/ct2/history/NCT01985126?A=24&B=25&C=merged -
Ja, når de forhåbentligt gode data fra MAIA bliver offentliggjort, burde vi vel stige omkring de 10%, som ved tilsvarende data fra Alcyone i august 17.
-
God morgen.:-)
-
BCMAxCD3 (JNJ-957) https://twitter.com/MM_Hub/status/1008277611238363136 https://learningcenter.ehaweb.org/eha/2018/stockholm/214621/kristine.frerichs.preclinical.evaluation.of.the.new.bcmaxcd3.bispecific.html?f=media=3*speaker=663389 https://clinicaltrials.gov/ct2/show/NCT03145181 http://www.genmab.com/product-pipeline/products-in-development/jnj-64007957#tab1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind